vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and iQSTEL Inc (IQST). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $84.2M, roughly 1.0× iQSTEL Inc). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -3.2%, a 26.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -14.9%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-1.2M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 28.0%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.
FDMT vs IQST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $84.2M |
| Net Profit | $19.4M | $-2.7M |
| Gross Margin | — | 3.5% |
| Operating Margin | 17.3% | -2.9% |
| Net Margin | 22.8% | -3.2% |
| Revenue YoY | 8508900.0% | -14.9% |
| Net Profit YoY | 139.1% | -44.5% |
| EPS (diluted) | $0.43 | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $84.2M | ||
| Q3 25 | $90.0K | $102.9M | ||
| Q2 25 | $15.0K | $72.2M | ||
| Q1 25 | $14.0K | $57.6M | ||
| Q4 24 | $1.0K | $98.9M | ||
| Q3 24 | $3.0K | $54.2M | ||
| Q2 24 | $5.0K | $78.6M | ||
| Q1 24 | $28.0K | $51.4M |
| Q4 25 | $19.4M | $-2.7M | ||
| Q3 25 | $-56.9M | $-2.3M | ||
| Q2 25 | $-54.7M | $-2.3M | ||
| Q1 25 | $-48.0M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-43.8M | $-773.0K | ||
| Q2 24 | $-35.0M | $-2.0M | ||
| Q1 24 | $-32.4M | $-580.2K |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 3.4% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | 17.3% | -2.9% | ||
| Q3 25 | -67983.3% | -0.5% | ||
| Q2 25 | -396373.3% | -0.9% | ||
| Q1 25 | -383007.1% | -1.0% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -1704400.0% | -0.1% | ||
| Q2 24 | -849120.0% | -0.4% | ||
| Q1 24 | -136200.0% | -0.4% |
| Q4 25 | 22.8% | -3.2% | ||
| Q3 25 | -63195.6% | -2.3% | ||
| Q2 25 | -364386.7% | -3.3% | ||
| Q1 25 | -342657.1% | -2.0% | ||
| Q4 24 | — | -1.9% | ||
| Q3 24 | -1461433.3% | -1.4% | ||
| Q2 24 | -699060.0% | -2.5% | ||
| Q1 24 | -115717.9% | -1.1% |
| Q4 25 | $0.43 | $-0.92 | ||
| Q3 25 | $-1.01 | $-0.68 | ||
| Q2 25 | $-0.98 | $-0.82 | ||
| Q1 25 | $-0.86 | $-0.44 | ||
| Q4 24 | — | $-1.19 | ||
| Q3 24 | $-0.79 | $-0.40 | ||
| Q2 24 | $-0.63 | $-0.90 | ||
| Q1 24 | $-0.66 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $2.2M |
| Total DebtLower is stronger | — | $4.1M |
| Stockholders' EquityBook value | $505.7M | $16.3M |
| Total Assets | $566.7M | $51.1M |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $2.2M | ||
| Q3 25 | $305.1M | $2.3M | ||
| Q2 25 | $293.2M | $2.0M | ||
| Q1 25 | $321.4M | $1.1M | ||
| Q4 24 | $424.9M | $2.5M | ||
| Q3 24 | $501.9M | $2.1M | ||
| Q2 24 | $541.9M | $797.2K | ||
| Q1 24 | $525.9M | $2.7M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $194.0K |
| Q4 25 | $505.7M | $16.3M | ||
| Q3 25 | $369.0M | $17.9M | ||
| Q2 25 | $420.9M | $14.3M | ||
| Q1 25 | $469.7M | $11.6M | ||
| Q4 24 | $510.6M | $11.9M | ||
| Q3 24 | $552.9M | $8.1M | ||
| Q2 24 | $588.3M | $7.6M | ||
| Q1 24 | $600.6M | $8.4M |
| Q4 25 | $566.7M | $51.1M | ||
| Q3 25 | $424.0M | $46.9M | ||
| Q2 25 | $473.6M | $51.4M | ||
| Q1 25 | $515.7M | $42.0M | ||
| Q4 24 | $560.4M | $79.0M | ||
| Q3 24 | $604.0M | $32.4M | ||
| Q2 24 | $620.1M | $30.0M | ||
| Q1 24 | $629.9M | $22.1M |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $-1.2M |
| Free Cash FlowOCF − Capex | $28.5M | $-1.2M |
| FCF MarginFCF / Revenue | 33.5% | -1.5% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-4.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $-1.2M | ||
| Q3 25 | $-46.5M | $-953.0K | ||
| Q2 25 | $-43.4M | $257.7K | ||
| Q1 25 | $-47.8M | $-1.9M | ||
| Q4 24 | $-134.6M | $-403.7K | ||
| Q3 24 | $-29.4M | $625.0K | ||
| Q2 24 | $-30.2M | $-2.6M | ||
| Q1 24 | $-29.1M | $-536.9K |
| Q4 25 | $28.5M | $-1.2M | ||
| Q3 25 | $-46.6M | $-969.2K | ||
| Q2 25 | $-43.4M | $211.7K | ||
| Q1 25 | $-48.4M | $-2.0M | ||
| Q4 24 | $-138.4M | $-421.3K | ||
| Q3 24 | $-31.2M | $594.5K | ||
| Q2 24 | $-30.6M | $-2.6M | ||
| Q1 24 | $-29.8M | $-608.5K |
| Q4 25 | 33.5% | -1.5% | ||
| Q3 25 | -51765.6% | -0.9% | ||
| Q2 25 | -289620.0% | 0.3% | ||
| Q1 25 | -345635.7% | -3.4% | ||
| Q4 24 | -13837100.0% | -0.4% | ||
| Q3 24 | -1038966.7% | 1.1% | ||
| Q2 24 | -611840.0% | -3.4% | ||
| Q1 24 | -106421.4% | -1.2% |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 101.1% | 0.0% | ||
| Q2 25 | 440.0% | 0.1% | ||
| Q1 25 | 4507.1% | 0.1% | ||
| Q4 24 | 378600.0% | 0.0% | ||
| Q3 24 | 59266.7% | 0.1% | ||
| Q2 24 | 6980.0% | 0.0% | ||
| Q1 24 | 2535.7% | 0.1% |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
IQST
| USA | $53.2M | 63% |
| Other | $29.9M | 35% |
| Switzerland | $1.1M | 1% |
